Abstract:We propose a non-invasive, folate receptor (FR)–based circulating tumor cell (CTC) detection approach to interpret treatment response of targeted therapy between baseline and follow-up CTC values and the feasibility whether CTCs as a prognostic factor in advanced NSCLC with EGFR mutation/ALK translocation. This was a prospective, unopen-labeled, single-center trial. From July 25, 2014 to March 11,2016, 308 advanced NSCLC patients were enrolled to quantified CTC level by negative enrichment using immunomagnetic beads in combination with folate receptor-directed polymerase chain reaction(PCR) that allows secondary amplification of tiny amounts of CTCs in 3mL peripheral blood before the start of targeted therapy and after one month, every two months hereafter of treatment. Among whom, 272 NSCLC patients with EGFR mutation (exon 19Del mutation: n=135, L858R mutation: n=137), 39 ALK translocation or undefined lung cancer patients. Sequential analyses were conducted to monitor CTC values during therapy and correlate radiological effects with treatment outcome. There was no significant difference between CTC values and patients’ characteristics including stage (P= 0.1015), EGFR mutation status (19 del:14.5 CTCs, L858R:12.6 CTCs, P=0.1868), age (≤60 versus >60 years), gender, smoking status. Of 272 eligible and evaluable patients received EGFR-TKI, we found that patients harboring lower CTC levels (<20.5) were associated with longer PFS (432 days, 95%CI:332.7-541.3) than those with higher CTC levels (≥20.5) (PFS: 308days, 95% CI: 245.3-370.7; P=0.017). Patients with CTC <20.5 had a DCR of 77.11% compared with 58.49% in CTC >20.5 groups (P=0.008), patients with CTC <20.5 had a ORR of 51.20% compared with 33.96% in CTC >20.5 groups (P=0.029). Decreased CTC values correlated well with partial response after one month or three months’ treatment of EGFR-TKI (P=0.0082 and P=0.0023), but not with stable disease (P=0.1843 and P=0.8606). Multivariate analysis showed that CTC level was an independent prognostic factor for PFS (CTC level<20.5 vs ≥20.5, hazard ratio, 0.497; P=0.014). The change of CTCs correlated significantly with radiological response. This strategy may enable non-invasive, predictive and prognostic, specific biomarker in patients undergoing targeted therapies.

Identification of α1-antitrypsin as a potential prognostic biomarker for advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors by proteomic analysis.

P2.03b-092 Predictive and Prognostic Effect of Circulating Tumor Cells in Non-Small Cell Lung Cancer Treated with Targeted Therapy: Topic: Biomarkers

Impact of Serum Vascular Endothelial Growth Factor and Interleukin-6 on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-cell Lung Cancer

Preliminary Analysis of Biomarkers in Plasma by Seldi to Predict the Response to Egfr Tyrosine Kinase Inhibitors (tkis) in Nsclc Patients.

Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Identification of GlcNAcylated Alpha-1-antichymotrypsin As an Early Biomarker in Human Non-Small-cell Lung Cancer by Quantitative Proteomic Analysis with Two Lectins

Proteins Associated with EGFR-TKIs Resistance in Patients with Non-Small Cell Lung Cancer Revealed by Mass Spectrometry.

Circulating Tumor Cells and Evaluation of Targeted Therapy Effect in Egfr Mutation/Alk Translocation Metastatic Non-Small Cell Lung Cancer

Prognostic and Predictive Value of Serum Carcinoembryonic Antigen Levels in Advanced Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Sensitive Mutations and Receiving Tyrosine Kinase Inhibitors.

Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study

Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung Cancer

Prediction of Epidermal Growth Factor Receptor Mutations in the Plasma/pleural Effusion to Efficacy of Gefitinib Treatment in Advanced Non-Small Cell Lung Cancer.

Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.

MA15.09 Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated with First-Line EGFR-TKIs

A Linear Discriminant Analysis Model Based on the Changes of 7 Proteins in Plasma Predicts Response to Anlotinib Therapy in Advanced Non-Small Cell Lung Cancer Patients

C-Reactive Protein To Albumin Ratio As Prognostic Markers In Patients With Advanced Non-Small Cell Lung Cancers Treated With Tyrosine Kinase Inhibitors

[Correlation Between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma].

Screening Anlotinib Responders Via Blood‐based Proteomics in Non‐small Cell Lung Cancer

Differentially expressed glycosylated patterns of α-1-antitrypsin as serum biomarkers for the diagnosis of lung cancer.

Discovery of Efficacy Biomarkers for Non-Small Cell Lung Cancer with First-Line Anti-Pd-1 Immunotherapy by Data-Independent Acquisition Mass Spectrometry